Laemmli SDS sample buffer, non-reducing (4X)
元素搜索元素搜索结构搜索结构搜索
Laemmli SDS sample buffer, non-reducing (4X)
Thermo Scientific Chemicals

Laemmli SDS sample buffer, non-reducing (4X)

Laemmli SDS sample buffer is used to prepare protein samples in the Laemmli SDS-PAGE system.
Have Questions?
更改视图buttonViewtableView
数量:
25 mL
50 mL
ChemDex试用 chem dexTM 网络 应用程序
货号 J63615.AD
又称 J63615-AD
价格（CNY)
-
数量:
50 mL
请求批量或定制报价
规格
最大浓度4X
适用于（应用）Laemmli SDS-PAGE
形式Liquid
数量50 mL
颜色Blue
查看更多内容
Laemmli SDS sample buffer is used for protein sample preparation to be used in the Laemmli SDS-PAGE system, The SDS detergent denatures the proteins and subunits and gives each an overall negative charge so that each will separate based on size. The bromophenol blue serves as a dye front that runs ahead of the proteins and also serves to make it easier to see the sample during loading.

This Thermo Scientific Chemicals brand product was originally part of the Alfa Aesar product portfolio. Some documentation and label information may refer to the legacy brand. The original Alfa Aesar product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.

General Description

  • Laemmli SDS sample buffer is composed of several compounds, including 375 mM Tris-HCl (pH 6.8), 9% SDS, 50% glycerol, 9% β-mercaptoethanol, 0.03% bromophenol blue
  • The SDS compound present in the Laemmli SDS sample buffer binds noncovalently to proteins. SDS is negatively charged and can mask the intrinsic charge of the protein it binds

Application

  • Laemmli SDS sample buffer is used to denature proteins and for protein sample preparation to be used in the SDS-PAGE system
  • This sample buffer is used as an electrophoretic dye for denaturation of proteins and monitoring the front of the running gel
  • It is also used for polyacrylamide protein gel analysis
RUO – Research Use Only

General References:

  1. Lee, G. S.; Kappler, K.; Porter, C. J. H.; Scanlon, M. J.; Nicolazzo, J. A. Fatty Acid Binding Proteins Expressed at the Human Blood-Brain Barrier Bind Drugs in an Isoform-Specific Manner. Pharm. Res. 2015, 32 (10), 3432-3446.
  2. Perot, E.; Enjolras, N.; Le Quellec, S.; Indalecio, A.; Girard, J.; Negrier, C.; Dargaud, Y. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity. Thromb. Res. 2015, 135 (5), 1017-1024.